The 22nd Orphan Drugs & Rare Diseases Global Congress 2025 Europe is dedicated to the critical issues shaping the future of Orphan Drugs.
The 22nd Orphan Drugs & Rare Diseases Global Congress 2025 Europe covers topics such as:
- Finding innovative and alternative ways in funding the development of Orphan Drugs
- What is Orphan Drugs’ role in sustainability of the Pharmaceutical Industry?
- What Do Developers Look for When Looking for an Outsourcing Partner?
- How commercially viable Is It to Engage in the Development of Orphan Drugs?
- Trends and Deal Structures in Licensing Agreements
- Coming Together in Developing Orphan Drugs and Crossing Borders
- Patient Access: How Can This Continue to Improve?
- How Can the Developer and the Patient Assist in the Evolution and Development of Orphan Drugs?
- What Do Insurance Companies Think About Orphan Drugs? Will They Make Modifications to Their Policies to Support Patients with Rare Diseases?
The 22nd Orphan Drugs & Rare Diseases Global Congress 2025 Europe brings together senior attendees with responsibilities in:
- Personalised Medicine
- Research and Development
- External R&D Innovation
- Regenerative Medicine
- Rare and Ultra-Rare Diseases
- Innovative Medicine
- Cell and Gene Therapy
- Therapeutic Are Lead
- Molecular Geneticist
- Translational Science
- Patient Advocacy Groups
- Program Management
- Public Affairs
- Patient Engagement
- Regulatory Affairs
- Medical Affairs
- Market Access
- Clinical Research Organizations
- Pricing and Reimbursement
- Managed and Early Access
- Commercial Development
- Health Economics Outcomes Research
- Product Specialist
- Investments and Funding
- Business Planning and Operations
- Global Strategic Services
- Academia
- Speciality Pharmacies
The 22nd Orphan Drugs & Rare Diseases Global Congress 2025 Europe might be held in London, United Kingdom in 2025.
